JNJ 78278343
Alternative Names: JNJ-78278343; JNJ-8343Latest Information Update: 28 Aug 2024
At a glance
- Originator Janssen Research & Development; Zymeworks
- Developer Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (SC)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (SC)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (SC)